# PHATHOM PHARMACEUTICALS, INC. (PHAT) · Edgar & Edgarette company card

> Phathom Pharmaceuticals (PHAT) grew revenue 217% in FY2025 to $175 million, operating margin -91.4% against a -3.8% median for pharmaceutical preparations, equity -169% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1783183 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/PHAT) · [JSON](https://www.pops4.com/boards/company/PHAT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $175M |
| Revenue growth, 1 year | 216.9% |
| Revenue growth per year | — |
| Operating margin | -91.4% (prior year -502.2%) |
| Net margin | -126.3% |
| Operating cash flow | −$167M |
| Capital spending | $229,000 |
| Free cash flow | −$167M |
| Cash | $130M |
| Long-term debt | $209M |
| Total assets | $259M |
| Total equity | −$438M |
| Equity ÷ assets | -169.1% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -21.03 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -1.38 (above the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -91.4% in FY2025

## Edgarette's reading

Exposure: revenue $175.1M (FY2025), total debt $209.1M. Experience: revenue up 216.9% on the year; operating margin -91.4%, up from -502.2%. Soundness: equity -169.1% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $437.8M and $703.6M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -91.4% against a -3.8% median; growth 216.9% against 13.7%.

Range logged 2026-11-19, receipt c6c7c3085e949ca0, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-11-18 ([filing](https://www.sec.gov/Archives/edgar/data/1783183/000119312526467065/0001193125-26-467065-index.htm))

## Recent filings

- 8-K · filed 2026-11-18 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1783183/000119312526467065/0001193125-26-467065-index.htm)
- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436961/0001193125-26-436961-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1783183/000119312526436959/0001193125-26-436959-index.htm)
- 8-K · filed 2026-10-26 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1783183/000119312526430977/0001193125-26-430977-index.htm)
- 8-K · filed 2026-10-23 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1783183/000119312526430621/0001193125-26-430621-index.htm)
- 8-K · filed 2026-09-29 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/0001193125-26-407696-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001783183.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1783183

## Cite

POPS4, Edgar & Edgarette: PHATHOM PHARMACEUTICALS, INC. (PHAT) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/PHAT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

